<DOC>
	<DOCNO>NCT01085123</DOCNO>
	<brief_summary>The purpose study determine central 5-HT1B receptor occupancy ZOMIG® Rapimelt ( zolmitriptan ) healthy male volunteer .</brief_summary>
	<brief_title>Determine Central 5-HT1B Receptor Occupancy ZOMIG® Rapimelt ( Zolmitriptan ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<criteria>Body mass index ≥19 ≤30 kg/m2 . A history presence neurological , haematological , psychiatric , gastrointestinal , hepatic , pulmonary , renal disease Use drug induce liver drug metabolise enzyme within 4 week first PET</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Migraine</keyword>
	<keyword>ZOMIG® Rapimelt</keyword>
</DOC>